<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00466609</url>
  </required_header>
  <id_info>
    <org_study_id>05/55628-8</org_study_id>
    <secondary_id>2005/55628-08</secondary_id>
    <nct_id>NCT00466609</nct_id>
  </id_info>
  <brief_title>Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment</brief_title>
  <acronym>EPMTOC</acronym>
  <official_title>Pharmacological Augmentation Strategies for Obsessive Compulsive Disorder Patients Non-respondent to First Line Medication Treatment: a Double Blind Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a controlled, randomized, double-blind and double-dummy study on the treatment
      augmentation strategy for obsessive compulsive disorder patients non-respondent to first line
      pharmacological treatment. The investigators will compare: fluoxetine maintenance at maximum
      dosage for additional 12 weeks; the association of fluoxetine with quetiapine; and the
      association of fluoxetine with clomipramine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arm 1: SSRI (Fluoxetine 40mg* once a day) + Clomipramine 75mg* once a day.

      Arm 2: SSRI (Fluoxetine 40mg* once a day) + Quetiapine 200mg* once a day.

      Arm 3: SSRI (Fluoxetine 80mg* once a day) + Placebo once a day.

      *or maximum tolerated dose

      We hypothesize that quetiapine and clomipramine will be effective augmentation strategies for
      resistant OCD patients in comparison to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>YBOCS</measure>
    <time_frame>12 weeks</time_frame>
    <description>Rates of improvement after 12 weeks of treatment based on the difference of initial and final Yale Brown Obsessive Compulsive Scale (YBOCS) scores for obsessions and compulsions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improvement of quality of life (QOL) will be assessed through SF-36 administered on weeks 0 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Adaptation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improvement of social adaptation using the Social Adaptation Scale (SAS) (Weissman &amp; Payket, 1974) administered on weeks 0 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>weeks 0,1,2,3,4,8,12</time_frame>
    <description>Tolerability of the proposed treatments through adverse events follow-up performed each visit (emphasis in serotonergic syndrome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Score obtained with Beck depression inventory (BDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BAI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Score obtained with Beck´s anxiety inventory (BAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinical global impression measure of improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiotoxicity</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change from baseline EKG regarding QT interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels</measure>
    <time_frame>weeks 2 and 12</time_frame>
    <description>Fluoxetine dosage and Clomipramine plasmatic dosages (when applies)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Obsessive Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Quetiapine (fluoxetine plus quetiapine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluoxetine up to 40mg once a day plus Quetiapine up to 200mg once a day, during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clomipramine (fluoxetine plus clomipramine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluoxetine up to 40mg once a day plus clomipramine up to 75mg once a day, during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (fluoxetine plus placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fluoxetine up to 80 mg once a day plus placebo 3 pills once a day, during 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomipramine (fluoxetine plus clomipramine)</intervention_name>
    <description>Clomipramine at maximum dosage of 75mg per day plus fluoxetine at maximum dosage of 40mg per day</description>
    <arm_group_label>Clomipramine (fluoxetine plus clomipramine)</arm_group_label>
    <other_name>Anafranil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine (fluoxetine plus quetiapine)</intervention_name>
    <description>Quetiapine at maximum tolerated dosage of 200mg per day plus fluoxetine at maximum dosage of 40mg per day</description>
    <arm_group_label>Quetiapine (fluoxetine plus quetiapine)</arm_group_label>
    <other_name>Seroquel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (fluoxetine plus placebo)</intervention_name>
    <description>Placebo plus fluoxetine at maximum dosage of 80mg per day</description>
    <arm_group_label>Placebo (fluoxetine plus placebo)</arm_group_label>
    <other_name>Prozac</other_name>
    <other_name>Daforin (EMS pharmaceutics)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. OCD diagnosis

          2. YBOCS score ≥ 16 (for patients with both obsessions and compulsions) or ≥ 10 (for
             patients with only obsessions or compulsions)

          3. Previously signed informed consent to participate in this clinical trial

        Exclusion Criteria:

          1. Patients with clinical or neurological diseases that may be worsen by the medications
             included in treatment protocol

          2. Current substance dependence or abuse

          3. Current psychotic symptoms

          4. Current suicide risk

          5. Current pregnancy or intention to get pregnant before the end of the treatment
             protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliana B Diniz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Psychiatry</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.ipqhc.org.br/</url>
    <description>Institutional site of main sponsor</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/22020357</url>
    <description>Main results</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/24288238</url>
    <description>Secondary analysis results</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2007</study_first_submitted>
  <study_first_submitted_qc>April 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Juliana Belo Diniz</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>clomipramine</keyword>
  <keyword>quetiapine</keyword>
  <keyword>fluoxetine</keyword>
  <keyword>placebo</keyword>
  <keyword>augmentation</keyword>
  <keyword>obsessive compulsive disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Clomipramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

